CristinaGasparettoMD

Oncology • Durham, NC

Associate Professor, Medicine, Duke University School of Medicine

Join to view full profile

Dr. Gasparetto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gasparetto's full profile

Already have an account?

Office
2400 Pratt St
Durham, NC 27705
Phone+1 919-668-1027
Is this information wrong?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1996 - 1999
Duke University HospitalResidency, Internal Medicine, 1993 - 1996
Sapienza University of RomeClass of 1986

Certifications & Licensure

NC State Medical License 1997 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2008 Jul 01
Terminated
Phase 1
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy Start of enrollment: 2008 Aug 01
Completed
Phase 2
Bortezomib With Melphalan and Prednisone for Multiple Myeloma Start of enrollment: 2004 Jul 01
Completed
Phase 2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT Start of enrollment: 2011 Feb 01
Terminated
Phase 1
Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2011 Nov 01
Terminated
Phase 1, Phase 2
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma Start of enrollment: 2013 Jan 01
Completed
Phase 1
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma Start of enrollment: 2012 Mar 01
Unknown status
Phase 1, Phase 2
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD Start of enrollment: 2013 Mar 01
Terminated
Phase 1
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma Start of enrollment: 2013 Jan 07
Active, not recruiting
Phase 1, Phase 2
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis Start of enrollment: 2013 Feb 01
Completed
Phase 1
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Start of enrollment: 2015 Jul 20
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.
Leslie Ballas, Sikander Ailawadhi, Mohit Narang, Cristina J Gasparetto, Hans C Lee, James W Hardin, Brian G M Durie, Kathleen Toomey, James Omel, Lynne I Wagner, Rafat...> ;Practical Radiation Oncology. 2023 Nov 19
9 citations
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H Tomasson, Michael A Damore, Sibo Jiang, Cynthia Basu, A...> ;Nature Medicine. 2023 Oct 1
2 citations
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
Gary J Schiller, Brea C Lipe, Nizar J Bahlis, Sascha A Tuchman, William I Bensinger, Heather J Sutherland, Suzanne Lentzsch, Muhamed Baljevic, Darrell White, Rami Kotb...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
7 citations
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Chenyu Lin, Rachel A DiCioccio, Tarek Haykal, William C McManigle, Zhiguo Li, Sarah M Anand, Jonathan C Poe, Sonali J Bracken, Wei Jia, Edwin P Alyea 3rd, Adela R Card...> ;Transplantation and Cellular Therapy. 2023 Mar 1
6 citations
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.
Yubin Kang, Pasupathi Sundaramoorthy, Cristina Gasparetto, Daniel Feinberg, Shengjun Fan, Gwynn Long, Emily Sellars, Anderson Garrett, Sascha A Tuchman, Brandi N Reeve...> ;Annals of Hematology. 2023 Feb 1
4 citations
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findin...
Hans C Lee, Karthik Ramasamy, Katja Weisel, Rafat Abonour, James W Hardin, Robert M Rifkin, Sikander Ailawadhi, Howard R Terebelo, Brian G M Durie, Derek Tang, Prashan...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Feb 1
10 citations
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
Muhamed Baljevic, Cristina Gasparetto, Gary J Schiller, Sascha A Tuchman, Natalie S Callander, Suzanne Lentzsch, Jorge Monge, Rami Kotb, Nizar J Bahlis, Darrell White,...> ;Ejhaem. 2022 Nov 1
2 citations
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the ...
Qaiser Bashir, Taiga Nishihori, Marcelo C Pasquini, Michael J Martens, Juan Wu, Melissa Alsina, Claudio Anasetti, Claudio Brunstein, Peter Dawson, Yvonne Efebera, Cris...> ;Transplantation and Cellular Therapy. 2023 Jun 1
4 citations
Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years.
Meagan V Lew, Yi Ren, Yen P Lowder, Sharareh Siamakpour-Reihani, Sendhilnathan Ramalingam, Kristi M Romero, Jillian C Thompson, Lauren M Bohannon, Jackie McIntyre, Hel...> ;Transplantation and Cellular Therapy. 2022 Aug 1
11 citations
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.
Anita D'Souza, Ruta Brazauskas, Edward A Stadtmauer, Marcelo C Pasquini, Parameswaran Hari, Asad Bashey, Natalie Callander, Steven Devine, Yvonne Efebera, Siddhartha G...> ;American Journal of Hematology. 2023 Jan 1
3 citations
Home-Based Hematopoietic Cell Transplantation in the United States.
Anthony D Sung, Vinay K Giri, Helen Tang, Krista Rowe Nichols, Meagan V Lew, Lauren Bohannon, Yi Ren, Sin-Ho Jung, Tara Dalton, Amy Bush, Jolien Van Opstal, Alexandra ...> ;Transplantation and Cellular Therapy. 2022 Apr 1
2 citations
Anaplastic Multiple Myeloma: Case Series and Literature Review.
Jian Wu, Emily Chu, Cristiana Costa Chase, Taewoong Choi, Cristina Gasparetto, Ken Young, Yubin Kang> ;Asploro Journal of Biomedical and Clinical Case Reports. 2022 Jan 15
18 citations
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Cristina Gasparetto, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Muhamed Baljevic, Suzanne Lentzsch, Adriana C Rossi, Rami Kotb, Darrell White, Nizar J....> ;British Journal of Cancer. 2021 Nov 20
2 citations
Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.
Patrick Smith, Meagan Lew, Yen P. Lowder, Kristi Romero, Jillian C. Thompson, Lauren Bohannon, Alyssa Pittman, Alexandra Artica, Sendhilnathan Ramalingam, Taewoong Cho...> ;Bone Marrow Transplantation. 2021 Oct 19
7 citations
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Karthik Ramasamy, Ajay K. Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A. Tuchman, Jacob P. Laubach, Cristina Gasparetto, Asher Chanan-Khan, Mar...> ;Blood Cancer Journal. 2021 Sep 3
10 citations
Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.
Cristina Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G.M. Durie, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, James W. Hardin, Lynne I. Wagner, Sikande...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Aug 29
11 citations
A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
Cristina Gasparetto, Kristian M. Bowles, Al-Ola Abdallah, Lura Morris, Gudrun Mander, Sheryl Coppola, Jing Wang, Jeremy A. Ross, Orlando F. Bueno, Emma Arriola, Maria-...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Aug 1
5 citations
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry.
Hans C. Lee, Sikander Ailawadhi, Cristina Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G.M. Durie, Mohit Narang, Howard R. Terebelo, Kathleen Toomey, James W....> ;Blood Cancer Journal. 2021 Jul 23
2 citations
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
Sendhilnathan Ramalingam, Sharareh Siamakpour-Reihani, Lauren Bohannan, Yi Ren, Alexander B. Sibley, Jeff Sheng, Li Ma, Andrew B. Nixon, Jing Lyu, Daniel C. Parker, Ja...> ;Plos One. 2021 Jun 25
5 citations
Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation
Prioty Islam, Helen Tang, Haesu Jin, Lauren Bohannon, Yi Ren, Nelson J. Chao, Taewoong Choi, Cristina Gasparetto, Mitchell E. Horwitz, Gwynn D. Long, Richard D. Lopez,...> ;Transplantation and Cellular Therapy. 2021 Sep 1
2 citations
Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.
Cindy M. Pabon, Zhiguo Li, Therese Hennig, Carlos M. de Castro, Jadee L. Neff, Mitchell E. Horwitz, Thomas W. LeBlanc, Gwynn D. Long, Richard D. Lopez, Anthony D. Sung...> ;Blood Cancer Journal. 2021 May 16
5 citations
Selinexor for the treatment of patients with previously treated multiple myeloma
Clifton C. Mo, Sundar Jagannath, Ajai Chari, Ajay K. Nooka, Sagar Lonial, David A. Siegel, Noa Biran, Cristina Gasparetto, Nizar J. Bahlis, Paul G. Richardson> ;Expert Review of Hematology. 2021 Jul 21
47 citations
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
Joseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, Ivan Spicka, Ravi Vij, Jeffrey A. Zonder, Djordj...> ;Blood Cancer Journal. 2021 May 12
3 citations
Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malig...
Lauren Bohannon, Helen Tang, Kristin Page, Yi Ren, Sin-Ho Jung, Alexandra Artica, Anne Britt, Prioty Islam, Sharareh Siamakpour-Reihani, Vinay K. Giri, Meagan Lew, Mat...> ;Transplantation and Cellular Therapy. 2021 May 12
14 citations
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma.
Cristina Gasparetto, Suzanne Lentzsch, Gary Schiller, Natalie Callander, Sascha Tuchman, Christine Chen, Darrell White, Rami Kotb, Heather Sutherland, Michael Sebag, M...> ;Ejhaem. 2021 Feb 1
Join now to see all

Journal Articles

Selinexor plus Low-Dose Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
Suzanne Lentzsch, Cristina Gasparetto, Blood

Abstracts/Posters

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)_CD3 Bispecific Antibody, in P...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory ...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect¬ MM Registry
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelate...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venet...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect¬ MM R...
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation
Cristina Gasparetto, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venet...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Effect of t(11;14) on outcomes of patients (pts) with newly diagnosed multiple myeloma (NDMM) in the connect MM registry.
2019 ASCO Annual Meeting - 6/1/2019
Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to Be Presented at the American Society of Hematology 2020 Annual MeetingNovember 4th, 2020
OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesApril 25th, 2019
Expert Highlights Early Promise of Selinexor in MyelomaFebruary 8th, 2018